Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2.
Widemann BC, Balis FM, Shalabi A, Boron M, O'Brien M, Cole DE, Jayaprakash N, Ivy P, Castle V, Muraszko K, Moertel CL, Trueworthy R, Hermann RC, Moussa A, Hinton S, Reaman G, Poplack D, Adamson PC. Widemann BC, et al. Among authors: shalabi a. J Natl Cancer Inst. 2004 Oct 20;96(20):1557-9. doi: 10.1093/jnci/djh270. J Natl Cancer Inst. 2004. PMID: 15494606
Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
Widemann BC, Balis FM, Kim A, Boron M, Jayaprakash N, Shalabi A, O'Brien M, Eby M, Cole DE, Murphy RF, Fox E, Ivy P, Adamson PC. Widemann BC, et al. Among authors: shalabi a. J Clin Oncol. 2010 Sep 1;28(25):3979-86. doi: 10.1200/JCO.2009.25.4540. Epub 2010 Aug 2. J Clin Oncol. 2010. PMID: 20679598 Free PMC article.
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G; task force on Methodology for the Development of Innovative Cancer Therapies. Smoragiewicz M, et al. Among authors: shalabi a. Ann Oncol. 2018 Nov 1;29(11):2175-2182. doi: 10.1093/annonc/mdy398. Ann Oncol. 2018. PMID: 30202892 Free article. Review.
PD-L1 blockade for cancer treatment: MEDI4736.
Ibrahim R, Stewart R, Shalabi A. Ibrahim R, et al. Among authors: shalabi a. Semin Oncol. 2015 Jun;42(3):474-83. doi: 10.1053/j.seminoncol.2015.02.007. Epub 2015 Feb 25. Semin Oncol. 2015. PMID: 25965366 Review.
The global landscape of cancer cell therapy.
Tang J, Hubbard-Lucey VM, Pearce L, O'Donnell-Tormey J, Shalabi A. Tang J, et al. Among authors: shalabi a. Nat Rev Drug Discov. 2018 Jul;17(7):465-466. doi: 10.1038/nrd.2018.74. Epub 2018 May 25. Nat Rev Drug Discov. 2018. PMID: 29795477 No abstract available.
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
Maio M, Coukos G, Ferrone S, Fox BA, Fridman WH, Garcia PL, Lahn M, Provendier O, Russo V, Rüttinger D, Shalabi A, Trajanoski Z, Viallet J, Wolchok JD, Ibrahim R. Maio M, et al. Among authors: shalabi a. Cancer Immunol Immunother. 2019 Jan;68(1):1-9. doi: 10.1007/s00262-018-2285-y. Epub 2018 Dec 18. Cancer Immunol Immunother. 2019. PMID: 30564889 Free PMC article.
132 results